Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | 0.0237 | 0.053 | 0.1248 |
Trypanosoma brucei | arginine N-methyltransferase, type II | 0.0916 | 0.592 | 1 |
Echinococcus multilocularis | nicotinamide phosphoribosyltransferase | 0.1076 | 0.7197 | 0.7186 |
Trichomonas vaginalis | shk1 kinase-binding protein, putative | 0.0916 | 0.592 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0498 | 0.2603 | 0.5 |
Brugia malayi | Pre-B cell enhancing factor precursor | 0.1076 | 0.7197 | 0.7186 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0498 | 0.2603 | 0.4166 |
Schistosoma mansoni | shk1 kinase-binding protein | 0.1429 | 1 | 1 |
Loa Loa (eye worm) | pre-B cell enhancing factor | 0.1076 | 0.7197 | 0.7186 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase, putative | 0.0237 | 0.053 | 0.052 |
Toxoplasma gondii | histone arginine methyltransferase PRMT5 | 0.1429 | 1 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.0498 | 0.2603 | 0.2574 |
Treponema pallidum | nicotinate phosphoribosyltransferase | 0.02 | 0.0234 | 0.5 |
Echinococcus multilocularis | protein arginine N methyltransferase 5 | 0.1429 | 1 | 1 |
Loa Loa (eye worm) | Skb1 methyltransferase | 0.1429 | 1 | 1 |
Echinococcus granulosus | protein arginine N methyltransferase 5 | 0.1429 | 1 | 1 |
Plasmodium vivax | protein arginine N-methyltransferase 5, putative | 0.1429 | 1 | 1 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase related pre-B cell enhancing factor | 0.02 | 0.0234 | 0.0196 |
Echinococcus granulosus | nicotinamide phosphoribosyltransferase | 0.1076 | 0.7197 | 0.7197 |
Entamoeba histolytica | Skb1 methyltransferase, putative | 0.1429 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0498 | 0.2603 | 0.2425 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0498 | 0.2603 | 0.4166 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase related pre-B cell enhancing factor | 0.1076 | 0.7197 | 0.7186 |
Brugia malayi | hypothetical protein | 0.0237 | 0.053 | 0.0493 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0498 | 0.2603 | 0.4166 |
Echinococcus granulosus | thymidylate synthase | 0.0498 | 0.2603 | 0.2603 |
Onchocerca volvulus | 0.0498 | 0.2603 | 1 | |
Echinococcus multilocularis | thymidylate synthase | 0.0498 | 0.2603 | 0.2574 |
Mycobacterium ulcerans | thymidylate synthase | 0.0498 | 0.2603 | 0.5 |
Trypanosoma cruzi | arginine N-methyltransferase, type II, putative | 0.0916 | 0.592 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0237 | 0.053 | 0.052 |
Brugia malayi | thymidylate synthase | 0.0498 | 0.2603 | 0.2574 |
Leishmania major | arginine N-methyltransferase, type II, putative;with=GeneDB:Tb927.10.640 | 0.0916 | 0.592 | 1 |
Trichomonas vaginalis | shk1 kinase-binding protein, putative | 0.0916 | 0.592 | 1 |
Plasmodium falciparum | protein arginine N-methyltransferase 5, putative | 0.1429 | 1 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0498 | 0.2603 | 1 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase | 0.02 | 0.0234 | 0.0196 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0498 | 0.2603 | 0.2574 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.4668 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.